Effect of Time to Surgery of Colorectal Liver Metastases on Survival

被引:0
作者
Emerson Y. Chen
Skye C. Mayo
Thomas Sutton
Matthew R. Kearney
Adel Kardosh
Gina M. Vaccaro
Kevin G. Billingsley
Charles D. Lopez
机构
[1] Oregon Health & Science University,Division of Hematology Oncology, Knight Cancer Institute
[2] Oregon Health & Science University,Division of Surgical Oncology, Knight Cancer Institute
来源
Journal of Gastrointestinal Cancer | 2021年 / 52卷
关键词
Colorectal cancer; Colorectal liver metastases; Chemotherapy; Clinical risk score; Time to surgery;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:169 / 176
页数:7
相关论文
共 271 条
[21]  
Hemminki A(2016)FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial Lancet Oncol 17 1426-59
[22]  
Sundquist J(2017)Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial JAMA 317 2392-undefined
[23]  
Hemminki K(2012)Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases? J Surg Oncol 105 55-undefined
[24]  
Scheele J(2015)Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial BMC Cancer 15 180-undefined
[25]  
Stangl R(undefined)undefined undefined undefined undefined-undefined
[26]  
Altendorf-Hofmann A(undefined)undefined undefined undefined undefined-undefined
[27]  
Kato T(undefined)undefined undefined undefined undefined-undefined
[28]  
Yasui K(undefined)undefined undefined undefined undefined-undefined
[29]  
Hirai T(undefined)undefined undefined undefined undefined-undefined
[30]  
Kanemitsu Y(undefined)undefined undefined undefined undefined-undefined